Trevi Therapeutics, Inc. (TRVI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$17.26+1.17%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TRVI
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | |
|---|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | ||||||||
| R&D Expenses | 41.4 | 33.5 | 39.4 | 23.7 | 19.8 | 23.0 | 22.3 | 19.3 |
| Operating Income | (59.6) | (49.3) | (51.5) | (33.9) | (29.9) | (32.5) | (32.5) | (26.6) |
| Earnings from Continuing Operations | ||||||||
| Interest Expense | — | — | 0.0 | 0.4 | 1.2 | 1.2 | 0.5 | 0.2 |
| Interest & Investment Income | 8.4 | 6.5 | 3.6 | 4.7 | — | — | — | — |
| Net Interest Expenses | — | — | — | (4.4) | — | — | — | — |
| Other Non-Operating Income / Expenses | 8.4 | 6.5 | 3.6 | 4.8 | 0.7 | (1.5) | (0.3) | 0.6 |
| EBT, Incl. Unusual Items | (51.2) | (42.8) | (47.9) | (29.1) | (29.2) | (34.0) | (32.8) | (26.1) |
| Income Tax Expense | (0.1) | (0.1) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) |
| Net Income | ||||||||
| Net Income | (51.1) | (42.8) | (47.9) | (29.1) | (29.2) | (33.9) | (32.8) | (26.1) |
| Per Share | ||||||||
| Basic EPS | (0.33) | (0.32) | (0.47) | (0.29) | (0.45) | (1.49) | — | — |
| Diluted EPS | (0.33) | (0.32) | (0.47) | (0.29) | (0.45) | (1.49) | — | — |
| Basic Weighted Avg Shares | 156.6 | 134.7 | 102.0 | 99.0 | 64.5 | 22.8 | — | — |
| Diluted Weighted Avg Shares | 156.6 | 134.7 | 102.0 | 99.0 | 64.5 | 22.8 | — | — |
| Supplemental | ||||||||
| EBITDA | — | (49.2) | (51.4) | (33.8) | (29.9) | — | — | — |
| EBIT | (59.6) | (49.3) | (51.5) | (33.9) | (29.9) | (32.5) | (32.5) | (26.6) |
| Effective Tax Rate | 0.1% | — | — | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.